

2018 FULL YEAR RESULTS PRESENTATION



MEDICLINIC RESULTS DISCLAIMER

This presentation contains certain forward-looking statements relating to the financial condition, the regulatory environment in which we operate, results of operations and businesses of Mediclinic and the Group, including certain plans and objectives of the Group.

All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in these statements.

Forward-looking statements include, among other things, statements concerning the potential exposure of Mediclinic to market risks and statements expressing management's expectations, beliefs, estimates, forecasts, projections and assumptions, including as to future potential cost savings, synergies, earnings, cash flow, production and prospects. These forward-looking statements are identified by their use of terms and phrases such as "anticipate", "believe", "could", "estimate", "expect", "goals", "intend", "may", "objectives", "outlook", "plan", "probably", "project", "risks", "seek", "should", "target", "will" and similar terms and phrases.

MEDICLINIC RESULTS AGENDA

INTRODUCTION

Page 4

FINANCIAL REVIEW

Page 7

OPERATIONAL REVIEW

Page 19

QUESTIONS AND ANSWERS

Page 24

APPENDIX

Page 25



INTRODUCTION

DANIE MEINTJES
CEO MEDICLINIC INTERNATIONAL



MEDICLINIC INTERNATIONAL






SUMMARY

STRONG MARKET FUNDAMENTALS	CONTINUED GROWTH IN DEMAND <ul style="list-style-type: none">• Ageing population and growing disease burden• Technological advances and consumerisation of services
DIVERSIFIED PRESENCE	ONE OF THE LARGEST PAN-EMEA HEALTHCARE GROUPS <ul style="list-style-type: none">• Leading market positions across all divisions; strong brand recognition• Developed and emerging markets exposure
LEVERAGING GLOBAL SCALE	EFFICIENT INTEGRATION OF OPERATING DIVISIONS <ul style="list-style-type: none">• Sharing clinical best practice, intellectual property and data analytics• Global procurement synergies
HIGH-QUALITY MANAGEMENT TEAM	30+ YEAR TRACK RECORD <ul style="list-style-type: none">• Experienced international executive and senior management teams• Financial discipline and strong cash flow generation

WELL POSITIONED TO DELIVER LONG-TERM VALUE TO SHAREHOLDERS

MEDICLINIC RESULTS HIGHLIGHTS

FY18 GROUP FULL YEAR RESULTS*

Revenue	EBITDA	Operating profit	Cash conversion
 4%  3% in CC	 3% Flat in CC EBITDA margin 17.9%	 3% EPS  1%	90% of adjusted EBITDA Final dividend 4.70 pence per share maintained

* Adjusted measures presented

Switzerland:	Hirslanden adapting to the changing regulatory environment; margin declined to 18.3%, as anticipated
Southern Africa:	Good second half revenue growth combined with cost management increased margin to 21.5%
Middle East:	Strong second half performance in Abu Dhabi; Continued delivery in Dubai; margin increased to 12.7%
Spire (UK):	Performance impacted by exceptional provisions in reported earnings

Current trading in line with expectations; guidance remains unchanged

FINANCIAL REVIEW

JURGENS MYBURGH
CFO MEDICLINIC INTERNATIONAL




ADJUSTED GROUP INCOME STATEMENT

£'m	FY18	FY17	% CHANGE
Revenue	2,870	2,749	4%
EBITDA	515	501	3%
<i>EBITDA margin</i>	17.9%	18.2%	
Depreciation and amortisation	(145)	(138)	5%
Other gains and losses	-	(3)	(100%)
Operating profit	370	360	3%
Net finance costs	(70)	(80)	(13%)
Taxation	(64)	(58)	10%
Income from associates	3	12	(75%)
Non controlling interests	(18)	(14)	29%
Earnings	221	220	1%
Earnings per share (pence)	30.0	29.8	1%
Dividend per share (pence)	7.90	7.90	-
<i>Weighted avg number of shares (m)</i>	737.1	736.9	

- Revenue growth reflects positive momentum in Southern Africa and Middle East; offset by impact of market and regulatory environment in Switzerland
- Cost management implemented in Southern Africa and Switzerland
- Depreciation increased due to ongoing investment
- Net finance costs benefitted from refinancing in Switzerland
- Reduced Spire contribution reflects lower reported earnings due to exceptional charges
- Normalised effective tax rate 20.8%
- Proposed final dividend maintained at 4.70p

GROUP REVENUE ANALYSIS



Hirslanden (47% of Group)

- Impacted by evolving changes in market and regulatory environment
- Incorporates Linde acquisition
- Up 2% in constant currency

Southern Africa (31% of Group)


- Strong second half performance partially offset first half weakness
- Continued weak macro-economic environment and funder interventions
- Up 5% in constant currency

Middle East (22% of Group)

- Continued good growth in Dubai
- Strong second half in Abu Dhabi
- Up 1% in constant currency


FY18 revenue increased 4% to £2,870m; up 3% in constant currency

REVENUE BRIDGE



- Constant currency revenue growth in Hirlanden, Southern Africa and Dubai
- Reduced offset from Abu Dhabi; positive second half momentum
- Reporting currency uplift

ADJUSTED EBITDA ANALYSIS



Hirslanden (48% of Group)

- Cost management initiatives implemented
- Down 7% in constant currency

Southern Africa (37% of Group)


- Patient volume impact more than offset by cost control measures
- Ongoing investment in quality care
- Up 6% in constant currency

Middle East (16% of Group)

- Reflects cost base post combination
- Up 9% in constant currency

FY18 adjusted EBITDA increased 3% to £515m; flat in constant currency

ADJUSTED EPS BRIDGE



* Refer to page 2 of the 2018 Full Year Results announcement for further details

GROUP BALANCE SHEET SUMMARY

£'m	31 Mar 18	31 Mar 17
Assets	6,343	7,422
Non-current assets:		
Property, equipment and vehicles	3,590	3,703
Intangible assets	1,406	2,156
Other non-current assets	386	494
Current assets	961	1,069
Equity and liabilities	6,343	7,422
Shareholders' funds	3,286	4,086
Non-controlling interests	87	78
Interest-bearing debt	1,937	2,030
Other long-term liabilities	579	707
Current liabilities	454	521
Net debt	(1,676)	(1,669)

- Currency impact
- Acquisitions, including Linde, added £140m to non-current assets
- Hirslanden impairment - £644m:
 - Property - £84m
 - Intangibles - £560m
- Spire impairment - £109m
- Successfully completed Hirslanden refinancing
- Net debt to EBITDA ratio flat at 3.3x

Maintaining a responsible approach to leverage

GROUP CASH FLOW SUMMARY

£'m	FY18	FY17*
Net cash flow from operating activities	345	377
Cash flow from investment activities	(319)	(201)
Investment to maintain operations	(112)	(101)
Investment to expand operations	(142)	(131)
Business combinations	(83)	-
Disposals	2	44
Other	16	(13)
Cash flow from financing activities	(108)	(169)
Distributions to non-controlling interests	(10)	(9)
Distributions to shareholders	(58)	(62)
Borrowings and other	(40)	(98)
Net increase/(decrease) in cash and cash equivalents	(82)	7
Closing balance of cash and cash equivalents	261	361


- Strong cash flow generation across all platforms impacted by receivables build-up:
 - Hirslanden billing process changes
 - Strong second half revenue increase in the Middle East
- Cash conversion at 90% of adjusted EBITDA (FY17: 98%)
- Linde acquisition funded through available cash

* Re-presented

GROUP CAPITAL EXPENDITURE

**TOTAL CAPITAL
EXPENDITURE
FY18 (£'m)**

**BUDGETED CAPITAL
EXPENDITURE
FY19 (£'m)***



- In constant currency, FY18 capex 3% below FY17:
 - Hirslanden capex down 20%
- FY19 budgeted capex up 18% on FY18:
 - MCME Parkview Hospital expansion capex
 - Investment to maintain and improve facilities

*Constant currency basis:
 GBP/CHF: 1.29
 GBP/ZAR: 17.22
 GBP/AED: 4.87

Focus on capital discipline and returns-orientated investment across the Group

** Excludes £83m associated with acquisitions in Switzerland

HIRSLANDEN

FINANCIAL OVERVIEW

CHF'm	FY18	FY17	% CHANGE
Revenue*	1,735	1,704	2%
EBITDA*	318	340	(7%)
<i>EBITDA* margin</i>	18.3%	20.0%	
Depreciation and amortisation	(110)	(98)	12%
Operating profit*	208	242	(14%)
Net finance costs* ^Δ	(62)	(73)	(15%)
Income tax expense*	(29)	(35)	(18%)
<i>Effective tax rate*</i>	19.7%	20.7%	
Earnings* ^Δ	117	134	(12%)
Movement in bed days sold	1.6%	(0.7%)	
Movement in revenue per bed day	(1.5%)	3.0%	
Inpatients (000's)	103	100	2.6%

- Revenue impacted by evolving changes in the market and regulatory environment
- 8% growth in outpatient revenue
- EBITDA* margin impacted by revenues; cost-management and efficiency measures implemented
- Finance costs benefited from refinance
- Cash conversion at 81% (FY17: 96%)
- Capex totalled CHF129m (FY17: CHF163m)

* Adjusted measures presented

^Δ Includes inter-company loan interest which is eliminated in the Group earnings reconciliation

MEDICLINIC SOUTHERN AFRICA

FINANCIAL OVERVIEW

ZAR'm	FY18	FY17	% CHANGE
Revenue	15,106	14,367	5%
EBITDA*	3,245	3,049	6%
<i>EBITDA* margin</i>	21.5%	21.2%	
Depreciation and amortisation	(496)	(465)	7%
Operating profit*	2,749	2,584	6%
Net finance costs	(526)	(496)	6%
Income tax expense	(684)	(582)	18%
<i>Effective tax rate</i>	30.7%	27.6%	
Non-controlling interests	(303)	(271)	12%
Earnings*	1,237	1,240	-
Movement in bed days sold	(1.5%)	0.8%	
Movement in revenue per bed day	6.7%	5.8%	
Admissions (000's)	566	579	(2.2)%

* Adjusted measures presented

- Lower patient volumes in first half impacted revenue; stronger second half performance
- Revenue per bed day increased due to inflation and mix change
- EBITDA* margin benefitted from focussed cost-management
- Cash conversion 103% (FY17: 104%)
- Capex totalled ZAR1 057m (FY17: ZAR1 305m)

MEDICLINIC MIDDLE EAST

FINANCIAL OVERVIEW

AED'm	FY18	FY17	% CHANGE
Revenue	3,134	3,109	1%
EBITDA*	397	364	9%
<i>EBITDA* margin</i>	12.7%	11.7%	
Depreciation and amortisation*	(149)	(173)	(14%)
Operating profit*	248	191	30%
Net finance costs	(34)	(31)	10%
Non-controlling interest	(4)	2	(295%)
Earnings*	210	162	30%
Movement in bed days sold	(3.5%)	(6.2%)**	
Inpatients ('000s)	72	69	3.2%
Outpatients ('000s)	2,866	3,173	(9.7%)

* Adjusted measures presented

** Compared to FY16 pro forma data

- Inflection point reached with strong second half revenue growth in Abu Dhabi
- Continued delivery in Dubai
- Quality of revenue improving due to business and operational alignment
- Depreciation increased due to opening of facilities
- Cash conversion 74% (FY17: 121%)
- Capex totalled AED389m (FY17: AED245m)

OPERATIONAL REVIEW

DANIE MEINTJES
CEO MEDICLINIC INTERNATIONAL





OPERATIONS HIRSLANDEN


OPERATIONS

-  Largest Swiss private hospital group; competitive mature healthcare market; delivering exceptional quality clinical care to wealthy ageing population
-  TARMED outpatient tariff reductions Jan 18
-  Outmigration of basic surgical procedures underway
-  Continued change in insurance mix
-  Adapting to current market and regulatory environment; focused on driving efficiencies and investing for future growth
-  Hirslanden 2020 strategic programme:
 - Standardise and centralise processes
 - Outpatient facilities
-  Acquired 115-bed Linde hospital in Biel

OPERATIONAL OVERVIEW



BED NUMBERS AND OCCUPANCY





OPERATIONS SOUTHERN AFRICA


OPERATIONS

- Leading market position with eight hospitals featured in Discovery Health's top 20 private hospitals
- Stable medical insurance membership offset by ageing population and increase in chronic diseases
- Affordability of healthcare a key focus for patients and medical insurance companies
- Continued investment in clinical services
- Rolling out 6 further day clinics in FY19-20
- New hospital at Stellenbosch
- Health Market Inquiry and National Health Insurance review both ongoing

OPERATIONAL OVERVIEW



BED NUMBERS AND OCCUPANCY





OPERATIONS MIDDLE EAST


OPERATIONS

- Well positioned to benefit from long-term growth opportunities in the UAE; building on our leading market position in Dubai
- Actions taken in Abu Dhabi have set the foundations for future growth; strong second half performance
- Investing in doctors, services and technology, new hospitals, expansion and upgrade projects and rebranding; divested several non-core assets
- Supporting new doctors to ramp up activity
- Delivering on insurance mix strategy to enhance the quality of revenue
- 182-bed Parkview Hospital opening Oct18; Airport Road expansion and Cancer Centre - FY20/21; Mediclinic Al Noor renovation and Western Region Hospital

OPERATIONAL OVERVIEW



ABU DHABI PATIENT MIX



MEDICLINIC INTERNATIONAL

KEY PRIORITIES

HIGH-QUALITY CARE

Deliver high-quality care focusing on our “Patients First” strategy



EFFICIENCY AND AFFORDABILITY

Focus on efficiencies to maintain affordability of healthcare



GROWTH OPPORTUNITIES

Consider new business opportunities and care delivery models



ONGOING INVESTMENT

Continue to invest in our people, facilities and services



LEVERAGING BENEFITS FROM A GLOBAL INTEGRATED GROUP

QUESTIONS AND ANSWERS

James Arnold

Head of Investor Relations
MEDICLINIC INTERNATIONAL PLC

14 Curzon Street
London
W1J 5HN
United Kingdom
Tel: +44 (0) 20 3786 8181
James.Arnold@Mediclinic.com
www.mediclinic.com


APPENDIX




MEDICLINIC INTERNATIONAL DIVERSIFIED GLOBAL FOOTPRINT

As at 31 March 2018


DISTRIBUTION OF THE GROUP'S
HOSPITALS



DISTRIBUTION OF THE GROUP'S
BEDS




DISTRIBUTION OF THE GROUP'S
EMPLOYEES




For the 12 months to 31 March 2018


CONTRIBUTION TO GROUP
REVENUE (£'M)



CONTRIBUTION TO GROUP
ADJUSTED EBITDA (£'M)



CONTRIBUTION TO GROUP
ADJUSTED EARNINGS (£'M)



■ Switzerland ■ Southern Africa ■ Middle East ■ UK ■ Corporate



MEDICLINIC INTERNATIONAL

FY19 GUIDANCE

HIRSLANDEN

- In FY19, expects modest revenue growth supported by an increase in average bed capacity for the year, largely related to Linde
- As a result of the regulatory and market trends more than offsetting the benefits of cost savings and efficiency initiatives, the FY19 EBITDA margin is expected to contract by around 100 basis points (“bps”) from the prior year
- EBITDA margin is targeted to gradually improve from FY20 onwards

MEDICLINIC SOUTHERN AFRICA

- FY19 revenue growth driven by 1-2% increase in bed days sold (largely as a result of increased productive days vs FY18) and tariff increases broadly in line with inflation
- The medium-term EBITDA margin is expected to be broadly in line with recent years

MEDICLINIC MIDDLE EAST

- FY19 revenue growth (adjusted for the adoption of IFRS15): low double-digit % range reflecting underlying operating performance of the business and additional bed capacity coming online in 2H19
- FY19 EBITDA margin of the existing operations expected to increase by c.250bps; continues improving year-on-year to c.20% in FY22
- Ramp up costs associated with the opening of Mediclinic Parkview Hospital in Dubai and upgrade and expansion projects in Abu Dhabi, offset the margin of the existing business by c.250bps per annum between FY19-FY21, reducing thereafter

Current FY19 trading across all platforms in line with expectations

FOREIGN EXCHANGE RATES

Average rates	FY18	FY17	% CHANGE
GBP/CHF	1.29	1.29	0.2%
GBP/ZAR	17.22	18.41	6.5%
GBP/AED	4.87	4.80	(1.5%)

Closing rates	FY18	FY17	% CHANGE
GBP/CHF	1.34	1.25	(7.0%)
GBP/ZAR	16.57	16.74	1.0%
GBP/AED	5.15	4.59	(12.2%)

GROUP DEBT STRUCTURE

31 MARCH 2018

MEDICLINIC SOUTHERN AFRICA	Carrying value ZARm	Carrying value £'m	Terms	Date repayable
Senior terms	4,683	283	3M Jibar +1.51% (ZAR 3,475m) and +1.69% (ZAR1,208m)	Jun 2019 and Dec 2020
Preference shares	3,316	200	Prime x 69% and 73%	Jun 2019 and 2020
Subsidiaries	131	8	Prime interest rate	1 to 12 years
Total debt	8,130	491		
Interest expense	659	38		
HIRSLANDEN	Carrying value CHFm	Carrying value £'m	Terms	Date repayable
Secured long-term bank loans	1,485	1,111	Swiss 3M Libor +1.25%	Oct 2023
Other secured bank loans	27	20	CHF 17m at Swiss 3M Libor +0.92%, CHF 10m at 0.9%	May and Dec 2023
Swiss bonds	235	176	CHF 145m at 1.625%, CHF90m at 2.0%	Feb 2021 & 2025
Secured long-term finance	2	2	Interest ranging between 1.0-12.0%	1 to 5 years
Total debt	1,749	1,309		
Interest expense*	62	48		
MEDICLINIC MIDDLE EAST	Carrying value AEDm	Carrying value £'m	Terms	Date repayable
Bank loans	707	137	3M Libor +2.50%	Jun 2020 & May 2021
Total debt	707	137		
Interest expense	38	8		
Total Group interest expense		94		
TOTAL GROUP DEBT (£'m)		1,937		
CASH AND CASH EQUIVALENTS (£'m)		(261)		
GROUP NET DEBT (£'m)		1,676		

* Includes derecognition of unamortised finance expenses and fair value gains on the ineffective Swiss interest rate swap

GROUP CAPITAL EXPENDITURE

FY18 Actual capex (£'m)	Hirslanden	Southern Africa	Middle East	Corporate	Total
To maintain operations	64	37	6	-	107
To expand operations	37	25	74	2	138
Total capital expenditure	101	62	80	2	245

FY19 Budgeted capex (£'m)*	Hirslanden	Southern Africa	Middle East	Corporate	Total
To maintain operations	60	49	17	-	126
To expand operations	42	27	93	1	163
Total capital expenditure	102	76	110	1	289


- FY19 capex budget up 18% on FY18:
 - MCME Parkview Hospital expansion and EHR
 - MCSA Investment to maintain and improve facilities and expansion of day clinics
 - Hirslanden in line with FY18 including Hirslanden 2020

* Constant currency basis: GBP/CHF: 1.29, GBP/ZAR: 17.22, GBP/AED: 4.87


FIVE YEAR OPERATIONAL SUMMARY

HIRSLANDEN

OPERATIONAL PERFORMANCE




PATIENT MIX



SOUTHERN AFRICA

OPERATIONAL PERFORMANCE





OPERATIONS HIRSLANDEN (SWITZERLAND)

OVERVIEW



HOSPITALS
17




CLINICS
4



BEDS
1,805



EMPLOYEES
9,635



DR OLE WIESINGER
CEO HIRSLANDEN



FLAGSHIP HOSPITAL HIRSLANDEN (SWITZERLAND)



KLINIK HIRSLANDEN – ZÜRICH



TOTAL BEDS

330

THEATRES

14 Incl. 1 hybrid

EMPLOYEES

c.1,800

ICU BEDS

20

MEDICAL DOCTORS

c.500



CAPITAL PROJECTS HIRSLANDEN

CAPITAL PROJECTS DURING FY18

Hospital	Project	Completion
Klinik St. Anna	MRI 3 Tesla	1H18
Klinik St. Anna	O-arm® Surgical Imaging system	1H18
Klinik Im Park	Outpatient surgery unit "Bellaria"	1H18
Klinik Hirslanden	Capacity expansion; gastroenterology & stroke unit	2H18
Klinik Permanence	Radiology institute "Cosmos"	2H18
Klinik Stephanshorn	DaVinci robot	2H18
Klinik Stephanshorn	Restructuring of entrance	2H18
Klinik Birshof	O-arm® Surgical Imaging system	2H18

FUTURE PROJECTS

Hospital	Project	Expected Completion
Klinik Hirslanden	HKL 1 Biplane	FY19
Klinik Hirslanden	Emergency practice with 8 beds	FY19
Klinik Im Park (Kappelistrasse)	Medical centre, breast centre, extension radiology	FY19
AndreasKlinik (Cham Lorze)	Doctor's offices	FY19
Klinik Birshof	Medical centre and intermediate care facility	FY19
Clinique La Colline	Sport medicine centre	FY19
Klinik Stephanshorn (Schuppis)	Doctor's offices	FY19
Klinik Hirslanden (Seefeldstrasse)	Doctor's offices	FY19
Klinik St. Anna	Ward C5 with 12 beds	FY19
St. Anna Im Bahnhof (Lucerne)	Outpatient Surgery Unit and medical centre	FY19
Klinik Linde	Extension of emergency unit, radiology	FY19
Salemspital	PETCT	FY19
Klinik Im Park	Renovation of 3 rd floor	FY 20



OPERATIONS SOUTHERN AFRICA

OVERVIEW



HOSPITALS

52



**DAY
CLINICS**

2




BEDS

8,131



EMPLOYEES

16,068



KOERT PRETORIUS
CEO MEDICLINIC SOUTHERN AFRICA



FLAGSHIP HOSPITAL SOUTHERN AFRICA

MEDICLINIC BLOEMFONTEIN



THEATRES	CATH LABS	PET	TOTAL BEDS	MRI'S	ICU BEDS	CONSULTANTS
12	2	1	383	2	75	70 Admitting



CAPITAL PROJECTS SOUTHERN AFRICA

CAPITAL PROJECTS DURING FY18

Hospital	Completion	Licenced Beds
<i>Growth into existing license</i>		
Mediclinic Bloemfontein (12 additional operational beds)	1H18	-
Mediclinic Vergelegen (20 additional operational beds)	2H18	-
Mediclinic Thabazimbi	2H18	13
Mediclinic Newcastle	2H18	30
Total licenced beds	As at FY18	8,131

FUTURE PROJECTS


Hospital	Expected Completion	Beds
<i>Existing hospitals</i>		
Mediclinic Stellenbosch	1H20	32
Mediclinic Legae	1H20	23
Mediclinic Vergelegen	1H20	8
Mediclinic Potchefstroom	2H20	70
Mediclinic Medforum	2H20	24
Mediclinic Tzaneen	2H21	35
<i>Day clinics</i>		
Mediclinic Newcastle Day Clinic	1H19	30 (3 theatres)
Mediclinic Nelspruit Day Clinic	1H20	16 (2 theatres)
Mediclinic Stellenbosch Day Clinic	2H20	30 (3 theatres)
Mediclinic Bloemfontein Day Clinic (awaiting license)	2H20	22 (2 theatres)
Mediclinic Pietermaritzburg	2H20	21 (3 theatres)
Mediclinic Cape Gate Day Clinic	2H20	20 (2 theatres)
<i>Additional/new facilities</i>		
Klerksdorp	Awaiting Competition Tribunal Hearing (May 2018)	256
Intercare	Completed DD – requires ComComm approval	
- Day clinics		92
- Sub-acute		128



OPERATIONS

MEDICLINIC MIDDLE EAST

OVERVIEW



DAVID HADLEY
CEO MEDICLINIC MIDDLE EAST



FLAGSHIP HOSPITALS

MEDICLINIC MIDDLE EAST

MEDICLINIC CITY HOSPITAL - DUBAI



**TOTAL
BEDS**

278

**OPERATING
THEATRES**

7

**PEADIATRIC ICU
BEDS**

6

**CATH
LAB**

1

NEW NORTH WING



**ICU
BEDS**

15

MRI

2

**NEONATAL ICU
BEDS**

27

CT

1



FLAGSHIP HOSPITALS

MEDICLINIC MIDDLE EAST



MEDICLINIC AIRPORT ROAD – ABU DHABI



HOSPITAL EXPANSION	PROJECT COMPLETION	NEONATAL ICU BEDS	TOTAL BEDS	CT	MRI	HIGH DEPENDANCY UNIT BEDS
100 beds	FY20/21	14	136	1	1	10
CANCER CENTRE & EXPANSION COMPLETE	TOTAL ICU BEDS	OPERATING THEATRES	CATH LAB			
FY20/21	16	14	1			



CAPITAL PROJECTS DUBAI



MEDICLINIC PARKVIEW HOSPITAL



BUDGET	TOTAL BEDS	PROJECT COMPLETION	ICU BEDS	CONSULTATION ROOMS	ER BEDS	NEONATAL ICU BEDS	CATH LAB	OPERATING THEATRES
AED680m	182	Oct 2018	15	100	19	22	1	5

SPIRE HEALTHCARE GROUP PLC

UNITED KINGDOM

- Mediclinic's 29.9% investment in Spire gives the Group exposure to UK private healthcare market
- Spire is ideally positioned to be a leading player in the independent hospital sector given its scale, reach and quality of care
- Underlying performance in 2017: revenue up 1%; EBITDA down 5% impacted by NHS tariff reductions
- Reported earnings impacted by provisions relating to civil litigation against a consultant who previously had practicing privileges at Spire Healthcare and ceasing to provide radiotherapy services at Spire Baddow in addition to other exceptional items
- Total Group admissions fell 1.7% as a result of growth in self pay (+6.4%) offset by declines in PMI (-4.1%) and NHS (-2.5) volumes
- In 2017, Spire opened two state of the art hospitals in Manchester and Nottingham, resolved the Ian Paterson civil litigation case, appointed Justin Ash as new CEO and received "Good" or "Outstanding" in all CQC inspections carried out
- 2018 guidance: financials to be in line with 2017
- Management announced "2022 Vision" of achieving 100% good/outstanding in CQC inspections and customer satisfaction/recommendation, 80% of revenues from private patients and an EBITDA of £200m